Advances in mRNA nanomedicines for malignant brain tumor therapy

Deng, Ting; Hasan, Ikram; Roy, Shubham; Liu, Yue; Zhang, Baozhu

doi:10.1016/j.smaim.2022.11.001

Cited by 8 publications

(4 citation statements)

References 88 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nucleic acid drugs, such as antisense oligonucleotide (ASO), small interfering RNA (siRNA), microRNA (miRNA) and messenger RNA (mRNA), have undergone rapid development in treating various diseases, including antiviral, anti-tumor, cardiac and metabolic diseases, liver diseases and many rare diseases [ 87 , 88 ]. In 2020, the first PCSK9-targeted siRNA drug (Inclisiran) was approved by the FDA for the treatment of hypercholesterolemia, which has also demonstrated a significant reduction in LDL cholesterol levels in atherosclerosis patients [ 89 ].…”

Section: Methodsmentioning

confidence: 99%

β-Cyclodextrin-based nanoassemblies for the treatment of atherosclerosis

Ji,

Zhang,

Shao

et al. 2024

Regenerative Biomaterials

View full text Add to dashboard Cite

Atherosclerosis, a chronic and progressive condition characterized by the accumulation of inflammatory cells and lipids within artery walls, remains a leading cause of cardiovascular diseases globally. Despite considerable advancements in drug therapeutic strategies aimed at managing atherosclerosis, more effective treatment options for atherosclerosis are still warranted. In this pursuit, the emergence of β-cyclodextrin (β-CD) as a promising therapeutic agent offers a novel therapeutic approach to drug delivery targeting atherosclerosis. The hydrophobic cavity of β-CD facilitates its role as a carrier, enabling the encapsulation and delivery of various therapeutic compounds to affected sites within the vasculature. Notably, β-CD-based nanoassemblies possess the ability to reduce cholesterol levels, mitigate inflammation, solubilize hydrophobic drugs and deliver drugs to affected tissues, making these nanocomponents promising candidates for atherosclerosis management. This review focuses on three major classes of β-CD-based nanoassemblies, including β-CD derivatives-based, β-CD/polymer conjugates-based and polymer β-CD-based nanoassemblies, highlighting a variety of formulations and assembly methods to improve drug delivery and therapeutic efficacy. These β-CD-based nanoassemblies exhibit a variety of therapeutic mechanisms for atherosclerosis and offer systematic strategies for overcoming barriers to drug delivery. Finally, we discuss the present obstacles and potential opportunities in the development and application of β-CD-based nanoassemblies as novel therapeutics for managing atherosclerosis and addressing cardiovascular diseases.

show abstract

Section: Methodsmentioning

confidence: 99%

β-Cyclodextrin-based nanoassemblies for the treatment of atherosclerosis

Ji,

Zhang,

Shao

et al. 2024

Regenerative Biomaterials

View full text Add to dashboard Cite

show abstract

“…[21] To address these limitations, non-viral carriers such as lipids, polymers, peptides, exosomes, and hybrid systems have garnered widespread attention for their efficacy and biosafety. [22][23][24][25][26][27][28] For example, lipid-based carriers have been employed in creating diverse RNA therapeutics, encompassing the pioneering siRNA drug ONPATTRO and the COVID-19 mRNA vaccines. [29][30][31] These lipid-based carriers have near-neutral charges at physiological pH but become positively charged in low-pH environments, enabling the successful escape of mRNA from endosomes/lysosomes while maintaining good biocompatibility.…”

Section: Introductionmentioning

confidence: 99%

Engineered mRNA Delivery Systems for Biomedical Applications

Wang,

Zhu,

Gan

et al. 2024

Advanced Materials

View full text Add to dashboard Cite

Messenger RNA (mRNA)‐based therapeutic strategies have shown remarkable promise in preventing and treating a staggering range of diseases. Optimizing the structure and delivery system of engineered mRNA has greatly improved its stability, immunogenicity, and protein expression levels, which has led to a wider range of uses for mRNA therapeutics. In this tutorial review, we first provide a thorough analysis of the optimization strategies used in the structure of mRNA and then describe delivery systems in great detail. Furthermore, we summarize the latest advancements in biomedical engineering for mRNA technology, including its applications in combatting infectious diseases, treating cancer, providing protein replacement therapy, conducting gene editing, and more. Lastly, we offer a perspective on forthcoming challenges and prospects concerning the advancement of mRNA therapeutics. Despite these challenges, mRNA‐based therapeutics remain promising, with the potential to revolutionize disease treatment and contribute to significant advancements in the biomedical field.This article is protected by copyright. All rights reserved

show abstract

“…The past three decades have witnessed a great expansion of research in the field of cancer nanomedicine. Various nanoparticles that include lipid-based nanoparticles, polymeric nanoparticles, and inorganic nanoparticles have been developed for targeted delivery of therapeutic nucleic acids, 1 chemotherapeutic agents, 2 or immunotherapeutic agents to tumors. 3 The advantage of using nanomedicines to treat cancer is that they can effectively target and deliver drugs to the tumor site, 4 reducing side effects and improving treatment efficiency.…”

Section: Introductionmentioning

confidence: 99%

Ginsenoside Rh2-Based Multifunctional Liposomes for Advanced Breast Cancer Therapy

Hong,

Wang,

Xia

et al. 2024

IJN

View full text Add to dashboard Cite

Background Most solid tumors are not diagnosed and treated until the advanced stage, in which tumors have shaped mature self-protective power, leading to off-target drugs and nanomedicines. In the present studies, we established a more realistic large tumor model to test the antitumor activity of a multifunctional ginsenoside Rh2-based liposome system (Rh2-lipo) on advanced breast cancer. Methods Both cholesterol and PEG were substituted by Rh2 to prepare the Rh2-lipo using ethanol-water system and characterized. The effects of Rh2-lipo on cell uptake, penetration of the tumor spheroid, cytotoxicity assay was investigated with 4T1 breast cancer cells and L929 fibroblast cells. The 4T1 orthotopic-bearing large tumor model was established to study the targeting effect of Rh2-lipo and inhibitory effect of paclitaxel loaded Rh2-lipo (PTX-Rh2-lipo) on advanced breast tumors. Results Rh2-lipo exhibit many advantages that address the limitations of current liposome formulations against large tumors, such as enhanced uptake in TAFs and tumor cells, high targeting and penetration capacity, cytotoxicity against TAFs, normalization of the vessel network, and depletion of stromal collagen. In in vivo study, PTX-Rh2-lipo effectively inhibiting the growth of advanced breast tumors and outperformed most reported PTX formulations, including Lipusu ® and Abraxane ® . Conclusion Rh2-lipo have improved drug delivery efficiency and antitumor efficacy in advanced breast cancer, which offers a novel promising platform for advanced tumor therapy.

show abstract

Advances in mRNA nanomedicines for malignant brain tumor therapy

Cited by 8 publications

References 88 publications

β-Cyclodextrin-based nanoassemblies for the treatment of atherosclerosis

β-Cyclodextrin-based nanoassemblies for the treatment of atherosclerosis

Engineered mRNA Delivery Systems for Biomedical Applications

Ginsenoside Rh2-Based Multifunctional Liposomes for Advanced Breast Cancer Therapy

Contact Info

Product

Resources

About